Replies to post #8180 on OncoSec Medical Inc (ONCSQ)

[trading.jeff]

Thanks for posting; nice find!!

I especially found the following excerpts to be of interest. They are from the first link, http://www.cancercommons.org/2014/01/07/melanoma-a-2013-progress-report/:

Only 15% to 20% of patients with advanced melanoma are expected to survive 5 years, and the average life expectancy for final-stage patients is about 9 months. With the advent of immune checkpoint blockade treatments, this statistic is bound to change. The first approved drug of this kind is ipilimumab (Yervoy), which was approved by the FDA in 2011. Recent analyses showed that even though only a few patients respond to treatment with Yervoy alone, those who do tend to stay disease-free for many years.

OncoSec's response rate is better than this.

ImmunoPulse performed well in a recent phase II trial. Remarkably, more than 60% of patients in the trial experienced shrinkage of other tumors in addition to the one chosen for injection.

Gee, I wonder where this came from!!

The second link,
IL-12 Therapy May Shrink Melanomas Not Directly Treated, when clicked opens this page:

OncoSec Medical Announces Positive Interim Data from Phase 2 Study of OMS-I100 in Metastatic Melanoma

http://www.benzinga.com/pressreleases/13/12/b4156911/oncosec-medical-announces-positive-interim-data-from-phase-2-study-of-o#ixzz2ndekZF8C

The third link,
DNA-based Immunotherapy for Melanoma Advances in Clinical Trials, also mentions OncoSec:

A promising new immunotherapy for melanoma is about to start a phase II clinical trial. Called ImmunoPulse, the two-step treatment entails injecting tumors with DNA that encodes an immune system protein called interleukin-12, and then delivering electric shocks to make the tumor cells absorb the DNA. These cells then produce interleukin-12, which boosts the immune response to the tumor. In an early trial of the new treatment on 13 people with melanoma, tumors shrank in all of them and hadn’t grown six months later in about half of them. The new trial will test how well this new immunotherapy controls the injected tumors as well as tumors elsewhere in the body, and results are expected in 6 months to a year, says ImmunoPulse developer OncoSec Medical Inc.

Six months to a year is right now.

$ONCS